NEXUS Biosystems Completes Majority Equity and Growth Financing with Telegraph Hill Partners

POWAY, Calif.--(BUSINESS WIRE)--NEXUS Biosystems, Inc. (“NEXUS”), a leading innovator and worldwide provider of automated sample management systems, today announced the closing of a majority equity and growth financing with Telegraph Hill Partners (“THP”).

The funds from this financing will be used to accelerate the commercialization of several of NEXUS’ new sample management products, including its new family of ultra-low temperature minus 80ºC BioStores. NEXUS also plans to significantly expand its manufacturing and customer support capabilities in order to rapidly commercialize new product innovations while continuing to provide superior customer service around the world.

“The demand for NEXUS products is continuing to grow at a strong pace throughout the US, Europe and Asia,” said John Lillig, President and CEO of NEXUS. “We have made major inroads into the pharmaceutical and biotech drug discovery markets with our next-generation NEXUS systems and we are just now entering into what is shaping up to be a very exciting automated ultra-low temperature BioStorage market. NEXUS is in the final stages of development of what we believe will be the world’s highest performance family of automated BioStorage systems that will help to provide high integrity management for the exploding growth of biological samples in biorepositories around the world. We are very excited to have the support of Telegraph Hill Partners, a premier life science industry investor, as we continue to expand into these rapidly growing markets.”

Concurrent with the financing, Deval Lashkari, Ph.D. and Glenn Novotny, both of Telegraph Hill Partners, joined NEXUS’ Board of Directors. “NEXUS has shown tremendous growth and penetration into the rapidly expanding market of automated storage and sample management,” said Deval Lashkari, Ph.D., Partner of THP. “We are delighted to be partners with NEXUS as it continues to bring innovative automation solutions to market.”

About NEXUS Biosystems, Inc.

NEXUS Biosystems is a leading innovator and worldwide provider of enabling technologies and automated sample management systems for pharmaceutical, biotech, agrichemical and research institutions worldwide. NEXUS products include the family of Universal Compound Store and Universal BioStore automated sample management systems, the XPeel plate de-sealer, and the Crystal Farm line of protein crystallization systems.

NEXUS Biosystems was founded in 2005, is headquartered in Poway, CA, has a European subsidiary ‘NEXUS Biosystems GmbH’ in Munich, Germany and has distribution offices throughout the US, Europe and Asia.

For further information about NEXUS, please visit www.nexusbio.com

About Telegraph Hill Partners

Telegraph Hill Partners is a San Francisco-based, private equity firm focused on investments in revenue-generating life science, medical technology and healthcare companies. THP invests in companies that have demonstrated commercial validation, possess superior economic business models and can achieve significant organic revenue growth. THP’s interdisciplinary team brings extensive sector expertise and investing experience spanning three decades. THP’s investments have included growth financings, secondary share purchases, corporate subsidiary acquisitions, recapitalizations and majority buyouts.

For further information about Telegraph Hill Partners, please visit www.telegraphhillpartners.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6001206&lang=en